HIV-1-specific Immune Responses in Subjects Who Temporarily Contain Virus Replication After Discontinuation of Highly Active Antiretroviral Therapy

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1999 Sep 24

PMID 10491418

Citations 49

Authors

G M Ortiz

D F Nixon

A Trkola

J Binley

X Jin

S Bonhoeffer

P J Kuebler

S M Donahoe

M A Demoitie

W M Kakimoto

T Ketas

B CLAS

J J Heymann

L Zhang

Y Cao

A Hurley

J P Moore

D D Ho

M Markowitz

Affiliations

Soon will be listed here.

Abstract

Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to suppression of HIV-1 plasma viremia to undetectable levels for 3 or more years. However, adherence to complex drug regimens can prove problematic, and subjects may temporarily discontinue HAART for variable periods. We studied 6 HIV-1-infected individuals who stopped therapy. Off HAART, levels of viremia were suppressed to fewer than 500 copies/mL in 2 subjects for more than 12 and more than 24 months, respectively, and in 1 subject for 4 months on 1 occasion. Three subjects failed to contain plasma viremia. Broad and strong HIV-1-specific immune responses were detected in subjects with prolonged suppression of viral replication. This longitudinal study suggests that containment of HIV-1 replication to low or undetectable levels after discontinuation of HAART is associated with strong virus-specific immune responses. Boosting of HIV-1-specific immune responses should be considered as an adjunctive treatment strategy for HIV-1-infected individuals on HAART.

Citing Articles

Brief Report: Toll-like Receptor 9-1635A/G Polymorphism Is Associated With HIV-1 Rebound After Four Weeks of Interruption of Antiretroviral Therapy.

Vallejo A, Molina-Pinelo S, De Felipe B, Abad-Fernandez M, Gonzalez-Escribano M, Leal M J Acquir Immune Defic Syndr. 2020; 85(2):252-256.

PMID: 32658127 PMC: 10019827. DOI: 10.1097/QAI.0000000000002437.

Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial.

Saxena D, Spino M, Tricta F, Connelly J, Cracchiolo B, Hanauske A PLoS One. 2016; 11(5):e0154842.

PMID: 27191165 PMC: 4871512. DOI: 10.1371/journal.pone.0154842.

No evidence of posttreatment control after early initiation of antiretroviral therapy.

Gianella S, Anderson C, Richman D, Smith D, Little S AIDS. 2015; 29(16):2093-7.

PMID: 26544575 PMC: 4638137. DOI: 10.1097/QAD.0000000000000816.

Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.

Sued O, Ambrosioni J, Nicolas D, Manzardo C, Aguero F, Claramonte X PLoS One. 2015; 10(7):e0131651.

PMID: 26186440 PMC: 4506046. DOI: 10.1371/journal.pone.0131651.

Effects of neutralizing antibodies on escape from CD8+ T-cell responses in HIV-1 infection.

Wikramaratna P, Lourenco J, Klenerman P, Pybus O, Gupta S Philos Trans R Soc Lond B Biol Sci. 2015; 370(1675).

PMID: 26150656 PMC: 4528488. DOI: 10.1098/rstb.2014.0290.

References

Koup R, Safrit J, Cao Y, Andrews C, McLeod G, Borkowsky W . Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994; 68(7):4650-5. PMC: 236393. DOI: 10.1128/JVI.68.7.4650-4655.1994. View

Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M . Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994; 68(9):6103-10. PMC: 237022. DOI: 10.1128/JVI.68.9.6103-6110.1994. View

Mellors J, Rinaldo Jr C, Gupta P, White R, Todd J, Kingsley L . Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996; 272(5265):1167-70. DOI: 10.1126/science.272.5265.1167. View

OBrien T, Blattner W, Waters D, Eyster E, Hilgartner M, Cohen A . Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996; 276(2):105-10. View

Purtscher M, Trkola A, Grassauer A, Schulz P, Klima A, Dopper S . Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS. 1996; 10(6):587-93. DOI: 10.1097/00002030-199606000-00003. View

Cao Y, Qin L, Zhang L, Safrit J, Ho D . Characterization of long-term survivors of human immunodeficiency virus type 1 infection. Immunol Lett. 1996; 51(1-2):7-13. DOI: 10.1016/0165-2478(96)02548-5. View

Borrow P, Lewicki H, Wei X, Horwitz M, Peffer N, Meyers H . Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med. 1997; 3(2):205-11. DOI: 10.1038/nm0297-205. View

Price D, Goulder P, Klenerman P, Sewell A, Easterbrook P, Troop M . Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A. 1997; 94(5):1890-5. PMC: 20013. DOI: 10.1073/pnas.94.5.1890. View

Vila J, Nugier F, Bargues G, Vallet T, Peyramond D, Hamedi-Sangsari F . Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet. 1997; 350(9078):635-6. DOI: 10.1016/S0140-6736(97)24035-3. View

10.

Wong J, Hezareh M, Gunthard H, Havlir D, Ignacio C, Spina C . Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278(5341):1291-5. DOI: 10.1126/science.278.5341.1291. View

11.

Finzi D, Hermankova M, Pierson T, Carruth L, Buck C, Chaisson R . Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278(5341):1295-300. DOI: 10.1126/science.278.5341.1295. View

12.

Rosenberg E, Billingsley J, Caliendo A, Boswell S, Sax P, Kalams S . Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997; 278(5342):1447-50. DOI: 10.1126/science.278.5342.1447. View

13.

Chun T, Stuyver L, Mizell S, Ehler L, Mican J, Baseler M . Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997; 94(24):13193-7. PMC: 24285. DOI: 10.1073/pnas.94.24.13193. View

14.

Connor R, Korber B, Graham B, Hahn B, Ho D, Walker B . Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol. 1998; 72(2):1552-76. PMC: 124637. DOI: 10.1128/JVI.72.2.1552-1576.1998. View

15.

Stephenson J . Studies reveal early impact of HIV infection, effects of treatment. JAMA. 1998; 279(9):641-2. View

16.

Ogg G, Jin X, Bonhoeffer S, Dunbar P, Nowak M, Monard S . Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998; 279(5359):2103-6. DOI: 10.1126/science.279.5359.2103. View

17.

Arya S . Antiretroviral therapy in countries with low health expenditure. Lancet. 1998; 351(9113):1433-4. DOI: 10.1016/S0140-6736(05)79479-4. View

18.

Morris L, Binley J, Clas B, Bonhoeffer S, Astill T, Kost R . HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med. 1998; 188(2):233-45. PMC: 2212446. DOI: 10.1084/jem.188.2.233. View

19.

Lisziewicz J, Jessen H, Finzi D, Siliciano R, Lori F . HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet. 1998; 352(9123):199-200. DOI: 10.1016/S0140-6736(98)24029-3. View

20.

Jin X, Roberts C, Nixon D, Cao Y, Ho D, Walker B . Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte responses and their relationship to vertical human immunodeficiency virus transmission. ARIEL Project Investigators. J Infect Dis. 1998; 178(5):1317-26. DOI: 10.1086/314455. View